



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 64983

Title: Advances in the Management of Cholangiocarcinoma

Reviewer's code: 05922885

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2021-02-26

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-03-17 01:44

Reviewer performed review: 2021-03-26 08:35

Review time: 9 Days and 6 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This paper presents recent advances in the management of cholangiocarcinoma with particular focus on the expanding role for liver transplantation, updated guidelines in the use of chemotherapy, novel applications of individualized therapy targeting the specific mutation profile of tumors, and management of malignant biliary obstruction. It is a topic of interest to the researchers in the related areas but the paper needs improvement before acceptance for publication. My detailed comments are as follows.

1. The topic is novel but the application proposed is not so novel.
2. "Tumor Directed Therapies", in this part, do the author make sure majority of the therapies had been summarized?
3. The targeted therapy and immunotherapy for cholangiocarcinoma was not comprehensive summarized. Please supply more information, including the results of correlated clinical researches in recent years.
4. Could the author offer fully spelling out the abbreviations to help the readers get more information and understand the review more correctly?
5. Make sure all the references in the right place and really support the author's point.